Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.
about
Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-AnalysisTreatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infectionsAcinetobacter baumannii: evolution of antimicrobial resistance-treatment optionsThe Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer PropertiesComparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill PatientsAntibiotics for ventilator-associated pneumonia.High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae.High dose of tigecycline for extremely resistant Gram-negative pneumonia: yes, we can.Therapy of Infections due to Carbapenem-Resistant Gram-Negative PathogensClinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria.Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis.How to treat VAP due to MDR pathogens in ICU patients.Piscidin is highly active against carbapenem-resistant Acinetobacter baumannii and NDM-1-producing Klebsiella pneumonia in a systemic Septicaemia infection mouse modelCarbapenemase-producing Enterobacteriaceae.Tigecycline does not prolong corrected QT intervals in healthy subjects.Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).Major variation in MICs of tigecycline in Gram-negative bacilli as a function of testing method.Clinical implications of antibiotic pharmacokinetic principles in the critically ill.New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections.Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review.Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies.Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in the nosocomial setting in Latin America.Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis.Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.Ventilator-associated pneumonia: present understanding and ongoing debates.Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria.Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment?Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant enterococci: Three major threats to hematopoietic stem cell transplant recipients.Tetracycline Antibiotics and Resistance.Use of Tigecycline in Pediatric Patients With Infections Predominantly Due to Extensively Drug-Resistant Gram-Negative Bacteria.Managing the oncologic patient with suspected pneumonia in the intensive care unit.Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.Sparing carbapenem usage.Controversies and advances in the management of ventilator associated pneumonia.Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.
P2860
Q26764796-91D4D917-0C41-4482-BEC8-78C43C1EB283Q26991886-2596534A-A163-4C4B-B927-96CB268A707BQ27015109-6DFB39D4-05AE-4FB6-BE53-51A7FA7B194DQ28076402-8FD871C0-7618-460D-A99F-C80AF76ABE92Q28550492-991A3AD7-02FF-42F3-8684-E92E0A05D88FQ30243877-3AB08453-4DDC-4080-9E0C-2094790EDAC4Q33754471-F749AC22-416A-4808-87F8-51F1091B55A6Q33816251-5480D5AA-F68D-4086-A70B-939F104B9877Q33822682-90467671-53E0-4E0D-B291-744AEF59656BQ34303970-8DDF8F49-4C4B-48B6-A858-F9A3ABC955C4Q35043721-0A471B31-8EFC-46D8-8EFE-26BC7E2B6B84Q35101242-F5F3BF70-DEE2-4AFD-A45E-34908FD1BD1CQ35457068-73656A82-43FD-4950-8E9F-9419DFF5C999Q35548903-54D372A2-8BF9-48A2-AAE1-85E5FBB0BD84Q35751615-8BAE761E-7D31-4DC9-97C9-DF55422BE03EQ36757583-63435BE8-1445-43F1-9001-EE36EC73AC49Q36761826-580E067D-7D80-4BD3-BF07-6E04056EF85BQ37377897-29F0B4BA-2675-46E7-BBA9-2AFAEB966713Q37713697-4E886EB4-6C54-43E5-AEF9-AA50E729A8BBQ38138835-B7C63CA9-256C-4D53-B99A-73F3EA03F3E2Q38179460-ECE076ED-3A77-4FE8-8109-EECDD7DE8706Q38212031-7D1A67F2-FB47-44D3-8B8F-72359978071FQ38231648-2C24AA39-4B7A-4D92-B74A-6D917A8F3F6AQ38232197-BE4CB9E9-A4DB-428E-9D1F-3810C8880F7AQ38243475-A555EF49-670D-4E11-ABA8-0A3257F10613Q38255278-80C2E073-DCDA-480F-91FD-12EE4364E8ACQ38262205-9F6F0748-C968-499D-8115-B32F99A96809Q38271775-9EE0ED37-43B2-457A-89C3-4DEA3AE1B75FQ38384662-708353EE-BB54-424A-8D35-CBDAA3162623Q38416932-CB4322AA-A7D3-475E-83C4-39A32BE994CDQ38532531-9DBF49B2-2963-44E0-8F2E-D88117DBC7A4Q38620812-CCA2C214-EADA-4BD1-A9A3-ABDCC5B7DBB5Q38779243-5D2796DF-0CF4-4D2B-8C10-8D6EDE68B0B9Q38783940-7D5C0936-9FBC-4C15-BC14-C47DFFB69A03Q38940456-6A015EC6-37F0-4631-81D6-4935E52A40D2Q38944862-A84055BA-A210-4D0C-8463-8E3E95318ECDQ39061989-9FFE65A2-37E6-4672-BE2E-A1BD606CE10CQ39388468-59485332-1CFB-4731-A701-A4B25139AC76Q40054170-8831E6A6-8E02-453C-8005-2FFA291C8514Q40175198-1D8498AC-5F16-429A-B99D-7A88B9778E60
P2860
Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Randomized phase 2 trial to ev ...... f hospital-acquired pneumonia.
@ast
Randomized phase 2 trial to ev ...... f hospital-acquired pneumonia.
@en
type
label
Randomized phase 2 trial to ev ...... f hospital-acquired pneumonia.
@ast
Randomized phase 2 trial to ev ...... f hospital-acquired pneumonia.
@en
prefLabel
Randomized phase 2 trial to ev ...... f hospital-acquired pneumonia.
@ast
Randomized phase 2 trial to ev ...... f hospital-acquired pneumonia.
@en
P2093
P2860
P356
P1476
Randomized phase 2 trial to ev ...... f hospital-acquired pneumonia.
@en
P2093
Hassan Gandjini
Jean Li Yan
Joan Korth-Bradley
Nathalie Dartois
Paul C McGovern
P2860
P304
P356
10.1128/AAC.01232-12
P407
P577
2013-01-28T00:00:00Z